The founders of Diabetology have been working in the field for over thirty years, and have accumulated a wealth of experience which has led to the development of its state-of-the-art technologies.
The disease is one which affects a large number of people in many different ways, and we believe our proprietary technologies, enabling ingestion of insulin and other protein drugs via the oral route, can bring back normality to the lives of diabetes and obesity sufferers. Oral insulin and oral GLP1’s are not only more convenient for the patient, but may avoid certain complications of the disease, improving the patients’ general health and well-being.
This is more important now than ever, in light of the increasing incidence of diabetes and obesity all over the world.
Our leadership team brings together deep industry expertise, strategic vision, and a commitment to innovation in Diabetology.
30 years of research & development in diabetes and obesity, and taking various products to market.
Cofounder funding support over 25 years. Contributed to over 1 million lives saved and $100m+ in third party Revenues
We have worked with over 30 leading medical institutions and research partners worldwide.
2024 – Australia
2011 – Europe
2010 – Europe
“At Diabetology, our mission is to translate scientific innovation into practical, safe, physiological, patient-centered solutions that improve metabolic health outcomes. We are committed to advancing research, precision formulation, and long-term therapeutic impact.”
Glen Travers
Co Founder
